VRTX AI Stock Analysis – Buy, Hold, or Avoid?
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) offers a compelling long-term investment case driven by industry-leading fundamentals, robust financial health, and a rich pipeline, though short-term technicals suggest caution. While the stock is currently in a bearish technical phase, its valuation is justified by strong margins and consistent growth, and sentiment remains positive with analysts forecasting substantial upside. Investors should consider timing entries carefully, but the overall risk/reward profile is attractive for those with a medium- to long-term horizon.
Fundamentals
Vertex Pharmaceuticals displays robust fundamental health, marked by steady revenue expansion, high profitability, and consistent earnings outperformance. Despite sector volatility, VRTX maintains industry-leading margins and strong operating discipline, supported by a deep pipeline and dominant positioning in cystic fibrosis therapies.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
7.82% YoY
Q1 2026
Net Income
59.59% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0B | 3.2B | 3.1B | 3.0B | 2.8B | 2.9B | 2.8B | 2.6B |
| Revenue Growth YoY | +7.82% | +10.82% | +10.99% | +12.06% | +3.09% | +15.66% | +11.61% | +6.11% |
| Net Income | 1.0B | 1.2B | 1.1B | 1.0B | 646.3M | 913.0M | 1.0B | -3.6B |
| Net Income Growth YoY | +59.59% | +30.46% | +3.59% | +128.74% | -41.22% | -5.76% | +0.98% | -492.44% |
| EPS | $4.06 | $4.69 | $4.24 | $4.02 | $2.52 | $3.55 | $4.05 | -$13.92 |
| EPS Growth YoY | +61.11% | +32.11% | +4.69% | +128.88% | -40.85% | -5.59% | +1.00% | -492.11% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.85% | 85.56% | 86.52% | 86.25% | 86.90% | 85.46% | 85.84% | 85.94% |
| Operating Margin | 38.10% | 40.30% | 38.56% | 38.83% | 22.75% | 35.23% | 40.27% | -132.85% |
| Net Margin | 34.53% | 36.91% | 35.20% | 34.84% | 23.33% | 31.35% | 37.71% | -135.83% |
| Return on Equity (ROE) | 5.33% | 6.38% | 6.25% | 6.01% | 3.92% | 5.56% | 6.69% | -24.32% |
| Return on Assets (ROA) | 4.13% | 4.84% | 4.64% | 4.59% | 3.03% | 4.43% | 5.14% | -19.74% |
Technical Analysis
VRTX is currently in a bearish trend with price trading below its 50, 150, and 200-day moving averages, indicating a topping phase and potential distribution. Momentum is neutral to fading, and RSI sits in the neutral zone without extreme signals. ADX suggests a strong trend is present, but technicals warn caution as smart money may be selling and volatility increases.
No extreme reading
Price in uptrend
Strong trend active
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Vertex Pharmaceuticals displays robust fundamental health, marked by steady revenue expansion, high profitability, and consistent earnings outperformance. Despite sector volatility, VRTX maintains industry-leading margins and strong operating discipline, supported by a deep pipeline and dominant positioning in cystic fibrosis therapies.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$4.47
Estimated
$4.24
Surprise
+$0.23
Surprise %
+5.42%
Revenue
Actual
$2.99B
Estimated
$2.99B
Surprise
-$7.3M
Surprise %
-0.24%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $4.47 | $5.03 | $4.80 | $4.52 | $4.06 | $3.98 | $4.38 | $-12.83 |
| EPS (Estimated) | $4.24 | $5.11 | $4.57 | $4.29 | $4.25 | $4.02 | $4.14 | $-11.63 |
| EPS Surprise | +$0.23 | -$0.08 | +$0.23 | +$0.23 | -$0.19 | -$0.04 | +$0.24 | -$1.20 |
| % Diff | +5.4% | -1.6% | +5.0% | +5.4% | -4.5% | -1.0% | +5.8% | -10.3% |
| Revenue | ||||||||
| Revenue (Actual) | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B | $2.77B | $2.63B |
| Revenue (Estimated) | $2.99B | $3.18B | $3.06B | $2.91B | $2.86B | $2.78B | $2.69B | $2.66B |
| Revenue Surprise | -$7.3M | +$5.76M | +$16.87M | +$58.44M | -$91.61M | +$127.84M | +$86.44M | -$28.96M |
| % Diff | -0.2% | +0.2% | +0.6% | +2.0% | -3.2% | +4.6% | +3.2% | -1.1% |
Valuation
Vertex Pharmaceuticals currently trades at a valuation that reflects both its robust earnings growth and the premium characteristic of the biotechnology sector. While its multiples are higher than the broader biotech industry average, they remain reasonable relative to peers and are supported by strong margins, consistent revenue growth, and positive analyst sentiment forecasting significant upside potential. This combination suggests a fundamentally solid valuation supported by growth and competitive positioning.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 27.50 | 24.16 | 23.11 | 27.66 | 48.18 | 28.39 | 28.69 | -8.46 |
| Price to Sales | 37.99 | 35.67 | 32.54 | 38.55 | 44.96 | 35.61 | 43.29 | 45.97 |
| Price to Book | 5.86 | 6.17 | 5.78 | 6.65 | 7.55 | 6.32 | 7.68 | 8.23 |
| Enterprise Value to EBITDA | 96.62 | 84.15 | 71.53 | 82.81 | 155.44 | 85.17 | 90.64 | -35.46 |
| Enterprise Value to Revenue | 36.81 | 35.30 | 31.53 | 37.39 | 43.87 | 34.64 | 42.01 | 44.60 |
Sentiment & Analyst Ratings
Vertex Pharmaceuticals displays a cautiously optimistic market sentiment driven by robust Q1 2026 earnings and solid pipeline progress, particularly in cystic fibrosis and novel disease area treatments. Despite some mixed investor reactions and concerns about slowing CF franchise growth and valuation levels, the overall analyst consensus remains strongly positive with substantial upside price targets.
Analyst Recommendations
Risk Assessment
Vertex Pharmaceuticals currently exhibits a strong financial position supported by robust liquidity and low leverage, reflecting a stable balance sheet. Despite steady revenue growth and solid earnings prospects, the company faces significant risks from competitive pressure in its cystic fibrosis franchise and uncertainties in its drug development pipeline. Overall, the investment risk is moderated by the firm's leading market position but tempered by execution and regulatory risks inherent to the biotech sector.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q1 2026
Quick Ratio
Latest Quarter: Q1 2026
Debt-to-Equity
Latest Quarter: Q1 2026
Debt-to-Assets
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 3.02 | 2.90 | 2.36 | 2.52 | 2.65 | 2.69 | 2.47 | 2.52 |
| Quick Ratio | 2.57 | 2.46 | 2.00 | 2.16 | 2.29 | 2.35 | 2.20 | 2.26 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.10 | 0.21 | 0.11 | 0.09 | 0.10 | 0.11 | 0.11 | 0.06 |
| Debt-to-Assets | 0.08 | 0.15 | 0.07 | 0.06 | 0.07 | 0.08 | 0.08 | 0.05 |
Liquidity Assessment
Current Ratio: 3.02(Strong)
Quick Ratio: 2.57(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.10(Low)
Debt-to-Assets: 0.08(Low)
The company has conservative debt levels, indicating low financial risk and strong long-term solvency.
Frequently Asked Questions about VRTX
AI Answers: Common Questions About VRTX
Get AI-powered answers to the questions investors ask most about Vertex Pharmaceuticals Incorporated
VRTX is a good long-term buy given its strong fundamentals (gross margin 86%, operating margin 38%+), consistent double-digit EPS growth, and fair valuation (P/E 25.5, above sector average but justified by profitability and pipeline). However, technicals suggest waiting for a better entry if you are a short-term trader, as the stock is below all major moving averages.
Unless your horizon is short-term and you are sensitive to technical weakness, there is no fundamental reason to sell; the investment thesis remains intact with robust earnings, strong pipeline, and positive analyst outlook. However, if the stock breaks below key support ($435), short-term traders may consider reducing exposure.
The biggest risks are high dependence on CF franchise revenues, clinical/regulatory setbacks in the pipeline, and future pricing/competition pressures. Financial risk is low (debt/equity 0.10, current ratio >3), but sector volatility and pipeline outcomes can impact returns.
Technical resistance is at $448 and $508, with support at $435 and $362; analysts have a median price target of $555 and upside scenarios up to $803. Near-term downside risk exists if $435 fails, but long-term targets remain well above current price.
VRTX is fairly valued at a P/E of 25.5, EV/EBITDA above sector median but near its historical average, and a premium P/S reflecting mature, recurring revenue. The valuation premium is justified by high margins, growth, and pipeline strength.
VRTX is fundamentally strong, with industry-leading profitability (gross margin 86%, net margin 32-37%), double-digit revenue and EPS growth, high ROE (low 20%), low leverage (debt/assets ~7.5%), and a robust, diversified pipeline.
Technical analysis is bearish: price is below 50, 150, and 200-day SMAs, RSI is neutral (45.7), and volatility is rising. Key support is at $435; a breakdown could lead to $362, while recovery above $448 would be needed for a bullish reversal.
Watch for upcoming pipeline readouts (gene-editing, sickle cell, pain), regulatory approvals, and new product launches. Quarterly earnings and expansion into new indications/territories are also key drivers for future upside.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.